CORMEDIX INC. Research and Development Expense
CORMEDIX INC. (CRMD) reported Research and Development Expense of $6.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- CORMEDIX INC. research and development expense for the quarter ending 2026-06-30 was $6.68M, a 173.71% increase year-over-year.
- CORMEDIX INC. research and development expense for the quarter ending 2026-03-31 was $7.21M, a 125.87% increase year-over-year.
- CORMEDIX INC. research and development expense for the quarter ending 2025-12-31 was $8.60M, a 398.14% increase year-over-year.
- CORMEDIX INC. research and development expense for the quarter ending 2025-09-30 was $5.10M, a 601.07% increase year-over-year.
- CORMEDIX INC. research and development expense for fiscal 2025 was $19.33M, a 390.44% increase from fiscal 2024.
- CORMEDIX INC. research and development expense for fiscal 2024 was $3.94M, a 70.03% decline from fiscal 2023.
- CORMEDIX INC. research and development expense for fiscal 2023 was $13.16M, a 23.18% increase from fiscal 2022.
- CORMEDIX INC. research and development expense for fiscal 2022 was $10.68M, a 18.68% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 59 month | Research and Development Expense 62 month | Research and Development Expense 65 month | Research and Development Expense 68 month | Research and Development Expense 71 month | Research and Development Expense 74 month | Research and Development Expense 77 month | Research and Development Expense 77 month as first filed | Research and Development Expense 80 month | Research and Development Expense 80 month as first filed | Research and Development Expense 83 month | Research and Development Expense 83 month as first filed | Research and Development Expense 89 month | Research and Development Expense 92 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.68M 10-Q · filed 2026-08-13 | $13.90M 10-Q · filed 2026-08-13 | $22.50M derived: sum of 3 quarters · filed 2026-08-13 | $27.59M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||||||||||
| 2026-03-31 | $7.21M 10-Q · filed 2026-05-14 | $15.81M derived: sum of 2 quarters · filed 2026-05-14 | $20.91M derived: sum of 3 quarters · filed 2026-05-14 | $23.35M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||||||||||
| 2025-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $13.70M derived: sum of 2 quarters · filed 2026-03-05 | $16.14M derived: sum of 3 quarters · filed 2026-08-13 | $19.33M 10-K · filed 2026-03-05 | ||||||||||||||||||
| 2025-09-30 | $5.10M 10-Q · filed 2025-11-12 | $7.54M derived: sum of 2 quarters · filed 2026-08-13 | $10.73M 10-Q · filed 2025-11-12 | $12.46M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||||||||||
| 2025-06-30 | $2.44M 10-Q · filed 2026-08-13 | $2.44M 10-Q · filed 2025-08-07 | $5.63M 10-Q · filed 2026-08-13 | $5.64M 10-Q · filed 2025-08-07 | $7.36M derived: sum of 3 quarters · filed 2026-08-13 | $8.09M derived: sum of 4 quarters · filed 2026-08-13 | ||||||||||||||||
| 2025-03-31 | $3.19M 10-Q · filed 2026-05-14 | $3.19M 10-Q · filed 2025-05-06 | $4.92M derived: sum of 2 quarters · filed 2026-05-14 | $5.65M derived: sum of 3 quarters · filed 2026-05-14 | $6.30M derived: sum of 4 quarters · filed 2026-05-14 | |||||||||||||||||
| 2024-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.45M derived: sum of 2 quarters · filed 2026-03-05 | $3.10M derived: sum of 3 quarters · filed 2026-03-05 | $3.94M 10-K · filed 2026-03-05 | $3.94M 10-K · filed 2025-03-25 | |||||||||||||||||
| 2024-09-30 | $727.12K 10-Q · filed 2025-11-12 | $1.38M derived: sum of 2 quarters · filed 2025-11-12 | $2.22M 10-Q · filed 2025-11-12 | $4.50M derived: sum of 4 quarters · filed 2025-11-12 | ||||||||||||||||||
| 2024-06-30 | $650.99K 10-Q · filed 2025-08-07 | $1.49M 10-Q · filed 2025-08-07 | $3.78M derived: sum of 3 quarters · filed 2025-08-07 | $6.44M derived: sum of 4 quarters · filed 2025-08-07 | ||||||||||||||||||
| 2024-03-31 | $837.45K 10-Q · filed 2025-05-06 | $3.13M derived: sum of 2 quarters · filed 2025-05-06 | $5.79M derived: sum of 3 quarters · filed 2025-05-06 | $10.59M derived: sum of 4 quarters · filed 2025-05-06 | ||||||||||||||||||
| 2023-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $4.95M derived: sum of 2 quarters · filed 2025-03-25 | $9.75M derived: sum of 3 quarters · filed 2025-03-25 | $13.16M 10-K · filed 2025-03-25 | ||||||||||||||||||
| 2023-09-30 | $2.66M 10-Q · filed 2024-10-30 | $7.46M derived: sum of 2 quarters · filed 2024-10-30 | $10.87M 10-Q · filed 2024-10-30 | $13.71M derived: sum of 4 quarters · filed 2024-10-30 | ||||||||||||||||||
| 2023-06-30 | $4.79M 10-Q · filed 2024-08-14 | $8.20M 10-Q · filed 2024-08-14 | $11.05M derived: sum of 3 quarters · filed 2024-08-14 | $13.38M derived: sum of 4 quarters · filed 2024-08-14 | ||||||||||||||||||
| 2023-03-31 | $3.41M 10-Q · filed 2024-05-09 | $6.25M derived: sum of 2 quarters · filed 2024-05-09 | $8.59M derived: sum of 3 quarters · filed 2024-05-09 | $11.80M derived: sum of 4 quarters · filed 2024-05-09 | ||||||||||||||||||
| 2022-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $5.18M derived: sum of 2 quarters · filed 2024-03-12 | $8.39M derived: sum of 3 quarters · filed 2024-03-12 | $10.68M 10-K · filed 2024-03-12 | ||||||||||||||||||
| 2022-09-30 | $2.34M 10-Q · filed 2023-11-14 | $5.55M derived: sum of 2 quarters · filed 2023-11-14 | $7.84M 10-Q · filed 2023-11-14 | $11.07M derived: sum of 4 quarters · filed 2023-11-14 | ||||||||||||||||||
| 2022-06-30 | $3.21M 10-Q · filed 2023-08-08 | $5.50M 10-Q · filed 2023-08-08 | $8.73M derived: sum of 3 quarters · filed 2023-08-08 | $13.47M derived: sum of 4 quarters · filed 2023-08-08 | ||||||||||||||||||
| 2022-03-31 | $2.29M 10-Q · filed 2023-05-15 | $5.52M derived: sum of 2 quarters · filed 2023-05-15 | $10.26M derived: sum of 3 quarters · filed 2023-05-15 | $12.78M derived: sum of 4 quarters · filed 2023-05-15 | ||||||||||||||||||
| 2021-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $7.98M derived: sum of 2 quarters · filed 2023-03-30 | $10.50M derived: sum of 3 quarters · filed 2023-03-30 | $13.13M 10-K · filed 2023-03-30 | ||||||||||||||||||
| 2021-09-30 | $4.74M 10-Q · filed 2022-11-10 | $7.26M derived: sum of 2 quarters · filed 2022-11-10 | $9.90M 10-Q · filed 2022-11-10 | $12.19M derived: sum of 4 quarters · filed 2022-11-10 | ||||||||||||||||||
| 2021-06-30 | $2.52M 10-Q · filed 2022-08-11 | $5.16M 10-Q · filed 2022-08-11 | $7.45M derived: sum of 3 quarters · filed 2022-08-11 | $10.38M derived: sum of 4 quarters · filed 2022-08-11 | ||||||||||||||||||
| 2021-03-31 | $2.64M 10-Q · filed 2022-05-12 | $4.93M derived: sum of 2 quarters · filed 2022-05-12 | $7.86M derived: sum of 3 quarters · filed 2022-05-12 | $13.54M derived: sum of 4 quarters · filed 2022-05-12 | ||||||||||||||||||
| 2020-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $5.22M derived: sum of 2 quarters · filed 2022-03-29 | $10.91M derived: sum of 3 quarters · filed 2022-03-29 | $13.38M 10-K · filed 2022-03-29 | ||||||||||||||||||
| 2020-09-30 | $2.93M 10-Q · filed 2021-11-09 | $8.61M derived: sum of 2 quarters · filed 2021-11-09 | $11.08M 10-Q · filed 2021-11-09 | $13.76M derived: sum of 4 quarters · filed 2021-11-09 | ||||||||||||||||||
| 2020-06-30 | $5.69M 10-Q · filed 2021-08-12 | $8.16M 10-Q · filed 2021-08-12 | $10.83M derived: sum of 3 quarters · filed 2021-08-12 | $13.36M derived: sum of 4 quarters · filed 2021-08-12 | ||||||||||||||||||
| 2020-03-31 | $2.47M 10-Q · filed 2021-05-13 | $5.15M derived: sum of 2 quarters · filed 2021-05-13 | $7.67M derived: sum of 3 quarters · filed 2021-05-13 | $10.65M derived: sum of 4 quarters · filed 2021-05-13 | ||||||||||||||||||
| 2019-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $5.20M derived: sum of 2 quarters · filed 2021-03-30 | $8.18M derived: sum of 3 quarters · filed 2021-03-30 | $11.05M 10-K · filed 2021-03-30 | ||||||||||||||||||
| 2019-09-30 | $2.52M 10-Q · filed 2020-11-05 | $5.50M derived: sum of 2 quarters · filed 2020-11-05 | $8.38M 10-Q · filed 2020-11-05 | $4.03M derived: sum of 4 quarters · filed 2020-11-05 | ||||||||||||||||||
| 2019-06-30 | $2.98M 10-Q · filed 2020-08-10 | $5.85M 10-Q · filed 2020-08-10 | $1.51M derived: sum of 3 quarters · filed 2020-08-10 | $9.80M derived: sum of 4 quarters · filed 2020-08-10 | ||||||||||||||||||
| 2019-03-31 | $2.87M 10-Q · filed 2020-05-11 | -$1.47M derived: sum of 2 quarters · filed 2020-05-11 | $6.82M derived: sum of 3 quarters · filed 2020-05-11 | $13.42M derived: sum of 4 quarters · filed 2020-05-11 | ||||||||||||||||||
| 2018-12-31 | -$4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $3.94M derived: sum of 2 quarters · filed 2020-03-16 | $10.54M derived: sum of 3 quarters · filed 2020-03-16 | $18.82M 10-K · filed 2020-03-16 | ||||||||||||||||||
| 2018-09-30 | $8.29M 10-Q · filed 2019-11-14 | $14.89M derived: sum of 2 quarters · filed 2019-11-14 | $23.17M 10-Q · filed 2019-11-14 | $31.63M derived: sum of 4 quarters · filed 2019-11-14 | ||||||||||||||||||
| 2018-06-30 | $6.60M 10-Q · filed 2019-08-14 | $6.60M 10-Q · filed 2018-08-14 | $14.88M 10-Q · filed 2019-08-14 | $23.34M derived: sum of 3 quarters · filed 2019-08-14 | $29.35M derived: sum of 4 quarters · filed 2019-08-14 | |||||||||||||||||
| 2018-03-31 | $8.28M 10-Q · filed 2019-05-13 | $16.74M derived: sum of 2 quarters · filed 2019-05-29 | $22.75M derived: sum of 3 quarters · filed 2019-05-29 | $27.84M derived: sum of 4 quarters · filed 2019-05-29 | ||||||||||||||||||
| 2017-12-31 | $8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-05-29 | $14.47M derived: sum of 2 quarters · filed 2019-05-29 | $19.56M derived: sum of 3 quarters · filed 2019-05-29 | $24.49M 10-K · filed 2019-05-29 | ||||||||||||||||||
| 2017-09-30 | $6.01M 10-Q · filed 2018-11-14 | $11.10M derived: sum of 2 quarters · filed 2018-11-14 | $16.03M 10-Q · filed 2018-11-14 | $16.03M derived: sum of 4 quarters · filed 2018-11-14 | ||||||||||||||||||
| 2017-06-30 | $5.09M 10-Q · filed 2018-08-14 | $10.01M 10-Q · filed 2018-08-14 | $10.02M derived: sum of 3 quarters · filed 2018-08-14 | $16.86M derived: sum of 4 quarters · filed 2018-08-14 | ||||||||||||||||||
| 2017-03-31 | $4.92M 10-Q · filed 2018-05-15 | $4.93M derived: sum of 2 quarters · filed 2018-05-15 | $11.77M derived: sum of 3 quarters · filed 2018-05-15 | $14.54M derived: sum of 4 quarters · filed 2018-05-15 | ||||||||||||||||||
| 2016-12-31 | $4.03K 10-K · filed 2017-03-16 | $6.84M derived: sum of 2 quarters · filed 2017-11-09 | $9.62M derived: sum of 3 quarters · filed 2017-11-09 | $15.74M 10-K · filed 2018-03-19 | ||||||||||||||||||
| 2016-09-30 | $6.84M 10-Q · filed 2017-11-09 | $9.61M derived: sum of 2 quarters · filed 2017-11-09 | $11.70M 10-Q · filed 2017-11-09 | $11.70M derived: sum of 4 quarters · filed 2017-11-09 | ||||||||||||||||||
| 2016-06-30 | $2.77M 10-Q · filed 2017-08-09 | $4.86M 10-Q · filed 2017-08-09 | $4.86M derived: sum of 3 quarters · filed 2017-08-09 | $4.87M derived: sum of 4 quarters · filed 2017-08-09 | ||||||||||||||||||
| 2016-03-31 | $2.09M 10-Q · filed 2017-05-10 | $2.09M derived: sum of 2 quarters · filed 2017-05-10 | $2.09M derived: sum of 3 quarters · filed 2017-05-10 | $2.09M derived: sum of 4 quarters · filed 2017-05-10 | ||||||||||||||||||
| 2015-12-31 | $1.49K 10-K · filed 2017-03-16 | $3.25K derived: sum of 2 quarters · filed 2017-03-16 | $5.05K derived: sum of 3 quarters · filed 2017-03-16 | $6.28M 10-K · filed 2017-03-16 | ||||||||||||||||||
| 2015-09-30 | $1.76K 10-K · filed 2017-03-16 | $1.76M 10-Q · filed 2015-11-12 | $3.56K derived: sum of 2 quarters · filed 2017-03-16 | $4.80M 10-Q · filed 2016-11-09 | $505.90K derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||||||||
| 2015-06-30 | $1.80K 10-K · filed 2017-03-16 | $1.80M 10-Q · filed 2015-08-06 | $3.03M 10-Q · filed 2016-08-04 | $504.13K derived: sum of 3 quarters · filed 2017-03-16 | $796.82K derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||||||||
| 2015-03-31 | $1.24K 10-K · filed 2017-03-16 | $1.23M 10-Q · filed 2015-05-07 | $502.33K derived: sum of 2 quarters · filed 2017-03-16 | $795.02K derived: sum of 3 quarters · filed 2017-03-16 | $966.95K derived: sum of 4 quarters · filed 2017-03-16 | |||||||||||||||||
| 2014-12-31 | $501.10K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $793.79K derived: sum of 2 quarters · filed 2017-03-16 | $965.72K derived: sum of 3 quarters · filed 2017-03-16 | $1.32M 10-K · filed 2017-03-16 | ||||||||||||||||||
| 2014-09-30 | $292.69K 10-Q · filed 2015-11-12 | $464.62K derived: sum of 2 quarters · filed 2015-11-12 | $817.63K 10-Q · filed 2015-11-12 | $658.53K derived: sum of 4 quarters · filed 2015-11-12 | ||||||||||||||||||
| 2014-06-30 | $171.93K 10-Q · filed 2015-08-06 | $524.95K 10-Q · filed 2015-08-06 | $365.84K derived: sum of 3 quarters · filed 2015-08-06 | $1.12M derived: sum of 4 quarters · filed 2015-08-06 | ||||||||||||||||||
| 2014-03-31 | $353.02K 10-Q · filed 2015-05-07 | $193.91K derived: sum of 2 quarters · filed 2015-05-07 | $944.68K derived: sum of 3 quarters · filed 2015-05-07 | $1.32M derived: sum of 4 quarters · filed 2015-05-07 | $24.78M 10-Q · filed 2014-05-15 | |||||||||||||||||
| 2013-12-31 | -$159.11K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $591.66K derived: sum of 2 quarters · filed 2015-03-12 | $971.84K derived: sum of 3 quarters · filed 2015-03-12 | $1.23M 10-K · filed 2015-03-12 | $24.43M 10-K · filed 2014-03-31 | |||||||||||||||||
| 2013-09-30 | $750.77K 10-Q · filed 2014-11-13 | $760.77K 10-Q · filed 2013-11-19 | $1.13M derived: sum of 2 quarters · filed 2014-11-13 | $1.39M 10-Q · filed 2014-11-13 | $1.42M 10-Q · filed 2013-11-19 | $1.68M derived: sum of 4 quarters · filed 2014-11-13 | $24.59M 10-Q/A · filed 2014-03-04 | $24.76M 10-Q · filed 2013-11-19 | ||||||||||||||
| 2013-06-30 | $380.17K 10-Q · filed 2014-08-14 | $390.17K 10-Q · filed 2013-08-14 | $635.21K 10-Q · filed 2014-08-14 | $655.21K 10-Q · filed 2013-08-14 | $932.80K derived: sum of 3 quarters · filed 2014-08-14 | $1.18M derived: sum of 4 quarters · filed 2014-08-14 | $23.84M 10-Q/A · filed 2014-03-04 | $24.00M 10-Q · filed 2013-08-14 | ||||||||||||||
| 2013-03-31 | $255.03K 10-Q · filed 2014-05-15 | $265.04K 10-Q · filed 2013-05-15 | $552.63K derived: sum of 2 quarters · filed 2014-05-15 | $797.12K derived: sum of 3 quarters · filed 2014-05-15 | $1.03M derived: sum of 4 quarters · filed 2014-05-15 | $23.46M 10-Q/A · filed 2014-03-04 | $23.61M 10-Q · filed 2013-05-15 | |||||||||||||||
| 2012-12-31 | $297.60K derived: 10-K 12 month − 10-Q/A 9 month · filed 2014-03-31 | $542.08K derived: sum of 2 quarters · filed 2014-03-31 | $779.02K derived: sum of 3 quarters · filed 2014-03-31 | $1.14M 10-K · filed 2014-03-31 | $1.19M 10-K · filed 2013-03-27 | $23.20M 10-K/A · filed 2014-03-04 | $23.34M 10-K · filed 2013-03-27 | |||||||||||||||
| 2012-09-30 | $244.49K 10-Q/A · filed 2014-03-04 | $255.74K 10-Q · filed 2012-11-13 | $481.43K derived: sum of 2 quarters · filed 2014-03-04 | $845.03K 10-Q/A · filed 2014-03-04 | $878.78K 10-Q · filed 2012-11-13 | $420.57K derived: sum of 4 quarters · filed 2014-03-04 | $23.03M 10-Q/A · filed 2013-03-27 | |||||||||||||||
| 2012-06-30 | $236.94K 10-Q/A · filed 2014-03-04 | $248.19K 10-Q/A · filed 2012-09-06 | $600.55K 10-Q/A · filed 2014-03-04 | $623.05K 10-Q/A · filed 2012-09-06 | $176.08K derived: sum of 3 quarters · filed 2014-03-04 | $1.90M derived: sum of 4 quarters · filed 2014-03-04 | $22.78M 10-Q/A · filed 2012-09-06 | |||||||||||||||
| 2012-03-31 | $363.61K 10-Q/A · filed 2014-03-04 | $374.86K 10-Q · filed 2012-05-15 | -$60.86K derived: sum of 2 quarters · filed 2014-03-04 | $1.66M derived: sum of 3 quarters · filed 2014-03-04 | $3.25M derived: sum of 4 quarters · filed 2014-03-04 | $22.53M 10-Q · filed 2012-05-15 | ||||||||||||||||
| 2011-12-31 | -$424.46K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2014-03-04 | $1.30M derived: sum of 2 quarters · filed 2014-03-04 | $2.88M derived: sum of 3 quarters · filed 2014-03-04 | $4.06M 10-K/A · filed 2014-03-04 | $4.10M 10-K · filed 2012-03-19 | $22.16M 10-K/A · filed 2012-04-26 | ||||||||||||||||
| 2011-09-30 | $1.72M 10-Q/A · filed 2013-03-27 | $3.31M derived: sum of 2 quarters · filed 2013-03-27 | $4.48M 10-Q/A · filed 2013-03-27 | $5.93M derived: sum of 4 quarters · filed 2013-03-27 | $22.54M 10-Q · filed 2011-11-10 | |||||||||||||||||
| 2011-06-30 | $1.58M 10-Q/A · filed 2012-09-06 | $2.76M 10-Q/A · filed 2012-09-06 | $4.20M derived: sum of 3 quarters · filed 2012-09-06 | $4.96M derived: sum of 4 quarters · filed 2012-09-06 | $20.82M 10-Q · filed 2011-08-09 | |||||||||||||||||
| 2011-03-31 | $1.18M 10-Q · filed 2012-05-15 | $2.62M derived: sum of 2 quarters · filed 2012-05-15 | $3.38M derived: sum of 3 quarters · filed 2012-05-15 | $3.94M derived: sum of 4 quarters · filed 2012-05-15 | ||||||||||||||||||
| 2010-12-31 | $1.45M derived: 10-K/A 12 month − 10-Q 9 month · filed 2012-04-26 | $2.21M derived: sum of 2 quarters · filed 2012-04-26 | $2.77M derived: sum of 3 quarters · filed 2012-04-26 | $5.49M 10-K/A · filed 2012-04-26 | ||||||||||||||||||
| 2010-09-30 | $760.53K 10-Q · filed 2011-11-10 | $1.32M derived: sum of 2 quarters · filed 2011-11-10 | $4.05M 10-Q · filed 2011-11-10 | |||||||||||||||||||
| 2010-06-30 | $560.69K 10-Q · filed 2011-08-09 | $3.29M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |